Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world comparison of second targeted therapies in metastatic renal cell carcinoma
NL-OMON23232Recruiting
- Sponsor
- Novartis
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of everolimus, sorafenib and axitinib in metastatic renal cell carcinoma (mRCC) (3 cohorts), sponsored by Novartis. Primary endpoints: Overall survival, Treatment duration and 1 more. Started Oct 2015; status: recruiting.
02
Drugs
everolimussorafenibaxitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NL-OMON23232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23232.